Medical School, Sigmund Freud University, Vienna, Austria.
Department of Internal Medicine V with Hematology, Oncology and Palliative Care, Hospital Hietzing, Wolkersbergenstraße 1, 1130, Vienna, Austria.
Wien Med Wochenschr. 2023 Feb;173(1-2):3-8. doi: 10.1007/s10354-022-00977-4. Epub 2022 Oct 25.
In a retrospective study, we analyzed the prevalence of increased creatinine levels in 166 patients with chronic myelomonocytic leukemia (CMML), their potential prognostic impact, and potential correlations with laboratory and molecular features. Increased creatinine values (> 1.1 mg/dl) were found in 71 of 166 (43%) patients. The median survival of patients with increased creatinine values was significantly shorter than in patients without impairment of renal function (20 vs. 52 months, p < 0.001). Patients with increased creatinine values were older, were more often male, had higher leukocyte counts, higher monocyte counts, and higher lactatdehydrogenase (LDH) values. There was a trend toward a higher prevalence of CBL and ASXL1 mutations in patients with renal impairment. Our findings show a high prevalence of renal abnormalities in patients with CMML. Increased creatinine values were identified as a new prognostic marker. These findings may be important for the individualized management of this heterogenous group of patients.
在一项回顾性研究中，我们分析了 166 例慢性髓单核细胞白血病（CMML）患者中肌酐水平升高的发生率、其潜在的预后影响以及与实验室和分子特征的潜在相关性。在 166 例患者中，有 71 例（43%）患者肌酐值升高。与肾功能未受损的患者相比，肌酐值升高的患者中位生存期明显缩短（20 个月 vs. 52 个月，p < 0.001）。肌酐值升高的患者年龄较大，男性较多，白细胞计数、单核细胞计数和乳酸脱氢酶（LDH）值较高。肾功能不全患者中 CBL 和 ASXL1 突变的发生率呈上升趋势。我们的研究结果显示 CMML 患者存在较高的肾脏异常发生率。肌酐值升高被确定为新的预后标志物。这些发现对于该异质性患者群体的个体化治疗可能很重要。
